{"url_path":"/sec/cpmd/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1081938/0001654954-26-005180-index.html","accession_number":"0001654954-26-005180","cik":"0001081938","ticker":"CPMD","issuer_name":"CANNAPHARMARX, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1081938/0001654954-26-005180-index.html","primary_entity_key":"0001081938","primary_entity_name":"CANNAPHARMARX, INC."},"word_count":8176,"has_tables":true,"body_markdown":"canna_10q.htm\n0001081938false--12-31Q120260.000167850140566250140562307610.00011.001.001.001000001000003000000744164550001000004550004550007441674416100000100000falsefalsefalsefalse0000003861400010819382026-01-012026-03-3100010819382026-02-012026-02-030001081938isdr:SingleOperatingSystemMember2026-01-012026-03-310001081938isdr:SingleOperatingSystemMember2025-01-012025-03-310001081938isdr:DeloitteLLPMember2026-03-310001081938isdr:StevenBarberMember2026-03-310001081938isdr:StevenBarberMember2025-12-310001081938isdr:FormerExecutivesMember2026-03-310001081938isdr:DeloitteLLPMember2025-12-310001081938isdr:AstorStreetLLCMember2023-03-012023-03-310001081938isdr:AstorStreetLLCMember2025-12-310001081938isdr:AstorStreetLLCMember2026-03-3100010819382022-04-300001081938isdr:MrAmirTalMember2025-01-012025-03-310001081938isdr:MrAmirTalMember2026-01-012026-03-310001081938isdr:MrZemelMember2026-01-012026-03-310001081938isdr:FormosaMember2025-01-012025-03-310001081938isdr:MrZemelMember2025-01-012025-03-310001081938isdr:PromissoryNoteWithFormosaMember2025-01-010001081938isdr:DnsCantekTwoThousandNinteenLtdMember2025-01-012025-03-310001081938isdr:DnsCantekTwoThousandNinteenLtdMember2026-01-012026-03-310001081938isdr:LTBManagementMemberisdr:ClassCPreferredStockMember2025-12-310001081938isdr:LTBManagementMemberisdr:ClassCPreferredStockMember2026-03-310001081938isdr:PromissoryNoteWithFormosaMember2026-01-012026-03-310001081938isdr:LTBManagementMemberisdr:MrAmirTalMemberisdr:NovemberTwentyTwoTwoThousandTwentyThreeMember2023-11-212023-11-220001081938isdr:MrZemelBMember2023-05-012023-05-250001081938isdr:MrZemelAMember2023-05-012023-05-250001081938isdr:LTBManagementMemberisdr:MrZemelMemberisdr:NovemberTwentyTwoTwoThousandTwentyThreeMember2023-11-212023-11-220001081938isdr:FabianVancottMember2025-01-012025-03-310001081938isdr:FabianVancottMember2026-01-012026-03-310001081938isdr:DominicColvinMember2026-01-012026-03-310001081938isdr:DominicColvinMember2025-12-310001081938isdr:DominicColvinMember2026-03-310001081938isdr:MrOrmanMember2025-12-310001081938isdr:MrOrmanMember2026-03-310001081938isdr:FabianVancottMember2026-03-310001081938isdr:FabianVancottMember2025-12-310001081938isdr:InvictusAccountingGroupLLPMember2025-12-310001081938isdr:LTBManagementMemberisdr:MrZemelMemberisdr:NovemberTwentyTwoTwoThousandTwentyThreeMember2026-01-012026-03-310001081938isdr:LTBManagementMemberisdr:MrZemelMemberisdr:NovemberTwentyTwoTwoThousandTwentyThreeMember2026-03-310001081938isdr:MrZemelAMember2026-03-310001081938isdr:MrZemelAMember2026-01-012026-03-310001081938isdr:MrZemelBMember2026-01-012026-03-310001081938isdr:MrZemelBMember2026-03-310001081938isdr:MrZemelCMember2026-03-310001081938isdr:MrZemelCMember2026-01-012026-03-310001081938isdr:MrZemelConvertibleNoteMember2026-01-012026-03-310001081938isdr:LTBManagementMemberisdr:MrAmirTalMemberisdr:NovemberTwentyTwoTwoThousandTwentyThreeMember2026-03-310001081938isdr:LTBManagementMemberisdr:MrAmirTalMemberisdr:NovemberTwentyTwoTwoThousandTwentyThreeMember2026-01-012026-03-310001081938isdr:MrAmirTalConvertibleNoteMember2026-03-310001081938isdr:MrAmirTalConvertibleNoteMember2026-01-012026-03-310001081938isdr:MrZemelMember2025-03-310001081938isdr:MrZemelMember2026-03-310001081938isdr:MrAmirTalConvertibleNoteMember2025-12-310001081938isdr:LTBManagementMemberisdr:MrAmirTalMemberisdr:NovemberTwentyTwoTwoThousandTwentyThreeMember2023-11-220001081938isdr:LTBManagementMemberisdr:MrAmirTalMemberisdr:NovemberTwentyTwoTwoThousandTwentyThreeMember2025-12-310001081938isdr:MrZemelCMember2025-12-310001081938isdr:MrZemelBMember2025-12-310001081938isdr:LTBManagementMemberisdr:MrZemelMemberisdr:NovemberTwentyTwoTwoThousandTwentyThreeMember2025-12-310001081938isdr:LTBManagementMemberisdr:MrZemelMemberisdr:NovemberTwentyTwoTwoThousandTwentyThreeMember2023-11-220001081938isdr:MrZemelAMember2025-12-310001081938isdr:FormosaMember2026-01-012026-03-310001081938isdr:MrZemelConvertibleNoteMember2026-03-310001081938isdr:MrZemelConvertibleNoteMember2025-12-310001081938isdr:InvictusAccountingGroupLLPMember2026-03-310001081938isdr:InvictusAccountingGroupLLPMember2026-01-012026-03-310001081938isdr:InvictusAccountingGroupLLPMember2025-01-012025-03-310001081938isdr:FormosaMember2025-12-310001081938isdr:FormosaMember2026-03-310001081938isdr:PromissoryNoteWithFormosaMember2026-03-310001081938isdr:MrTalCNMember2026-03-310001081938isdr:KozeCnMember2026-03-310001081938isdr:KozeCnMember2025-12-310001081938isdr:MrTalLTBMember2026-03-310001081938isdr:KozeCMember2026-03-310001081938isdr:KozesBMember2026-03-310001081938isdr:KozeAMember2026-03-310001081938isdr:KozeLtbMember2026-03-310001081938isdr:PromissoryNoteWithFormosaMember2025-12-310001081938isdr:MrTalCNMember2025-12-310001081938isdr:MrTalLTBMember2025-12-310001081938isdr:KozeCMember2025-12-310001081938isdr:KozesBMember2025-12-310001081938isdr:KozeAMember2025-12-310001081938isdr:KozeLtbMember2025-12-310001081938us-gaap:RelatedPartyMember2025-12-310001081938us-gaap:RelatedPartyMember2026-03-310001081938us-gaap:RelatedPartyMember2026-01-012026-03-310001081938us-gaap:RelatedPartyMember2025-01-012025-03-3100010819382025-01-012025-12-310001081938us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001081938us-gaap:RetainedEarningsMember2026-03-310001081938us-gaap:AdditionalPaidInCapitalMember2026-03-310001081938us-gaap:TreasuryStockCommonMember2026-03-310001081938isdr:SharesToBeIssuedMember2026-03-310001081938us-gaap:CommonStockMember2026-03-310001081938isdr:PreferredStockSeriesCMember2026-03-310001081938isdr:PreferredStockSeriesBMember2026-03-310001081938isdr:PreferredStockSeriesAMember2026-03-310001081938us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001081938us-gaap:RetainedEarningsMember2026-01-012026-03-310001081938us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001081938us-gaap:TreasuryStockCommonMember2026-01-012026-03-310001081938isdr:PreferredStockSeriesCMember2026-01-012026-03-310001081938isdr:PreferredStockSeriesBMember2026-01-012026-03-310001081938isdr:PreferredStockSeriesAMember2026-01-012026-03-310001081938isdr:SharesToBeIssuedMember2026-01-012026-03-310001081938us-gaap:CommonStockMember2026-01-012026-03-310001081938us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001081938us-gaap:RetainedEarningsMember2025-12-310001081938us-gaap:AdditionalPaidInCapitalMember2025-12-310001081938us-gaap:TreasuryStockCommonMember2025-12-310001081938isdr:SharesToBeIssuedMember2025-12-310001081938us-gaap:CommonStockMember2025-12-310001081938isdr:PreferredStockSeriesCMember2025-12-310001081938isdr:PreferredStockSeriesBMember2025-12-310001081938isdr:PreferredStockSeriesAMember2025-12-3100010819382025-04-012025-12-310001081938us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-12-310001081938us-gaap:RetainedEarningsMember2025-04-012025-12-310001081938us-gaap:AdditionalPaidInCapitalMember2025-04-012025-12-310001081938us-gaap:TreasuryStockCommonMember2025-04-012025-12-310001081938isdr:SharesToBeIssuedMember2025-04-012025-12-310001081938us-gaap:CommonStockMember2025-04-012025-12-310001081938isdr:PreferredStockSeriesCMember2025-04-012025-12-310001081938isdr:PreferredStockSeriesBMember2025-04-012025-12-310001081938isdr:PreferredStockSeriesAMember2025-04-012025-12-310001081938us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001081938us-gaap:RetainedEarningsMember2025-03-310001081938us-gaap:AdditionalPaidInCapitalMember2025-03-310001081938isdr:SharesToBeIssuedMember2025-03-310001081938us-gaap:TreasuryStockCommonMember2025-03-310001081938us-gaap:CommonStockMember2025-03-310001081938isdr:PreferredStockSeriesCMember2025-03-310001081938isdr:PreferredStockSeriesBMember2025-03-310001081938isdr:PreferredStockSeriesAMember2025-03-310001081938us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001081938us-gaap:RetainedEarningsMember2025-01-012025-03-310001081938us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001081938us-gaap:TreasuryStockCommonMember2025-01-012025-03-310001081938isdr:SharesToBeIssuedMember2025-01-012025-03-310001081938us-gaap:CommonStockMember2025-01-012025-03-310001081938isdr:PreferredStockSeriesCMember2025-01-012025-03-310001081938isdr:PreferredStockSeriesBMember2025-01-012025-03-310001081938isdr:PreferredStockSeriesAMember2025-01-012025-03-310001081938us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001081938us-gaap:RetainedEarningsMember2024-12-310001081938us-gaap:AdditionalPaidInCapitalMember2024-12-310001081938us-gaap:TreasuryStockCommonMember2024-12-310001081938isdr:SharesToBeIssuedMember2024-12-310001081938us-gaap:CommonStockMember2024-12-310001081938isdr:PreferredStockSeriesCMember2024-12-310001081938isdr:PreferredStockSeriesBMember2024-12-310001081938isdr:PreferredStockSeriesAMember2024-12-3100010819382025-03-3100010819382024-12-3100010819382025-01-012025-03-310001081938us-gaap:SeriesCPreferredStockMember2025-12-310001081938us-gaap:SeriesCPreferredStockMember2026-03-310001081938isdr:SeriesBPreferredStocksMember2025-12-310001081938isdr:SeriesBPreferredStocksMember2026-03-310001081938us-gaap:SeriesAPreferredStockMember2025-12-310001081938us-gaap:SeriesAPreferredStockMember2026-03-3100010819382025-12-3100010819382026-03-3100010819382026-05-20iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pureiso4217:CAD\n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 10-Q**\n\n \n\n☒     QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\nFor the quarterly period ended **March 31, 2026**\n\n \n\n**or**\n\n \n\n☐     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\nFor the transition period from ___________to ___________\n\n \n\nCommission File Number: **000-27055**\n\n \n\n**CANNAPHARMARX, INC.**\n\n(Exact name of small business issuer as specified in its charter)\n\n \n\n**Delaware**\n\n \n\n**27-4635140**\n\n(State of other jurisdiction of incorporation)\n\n \n\n(IRS Employer ID No.)\n\n \n\n**4439 Township Rd 304,**\n\n**Mountain View County, Alberta, Canada T0M 0R0**\n\n(Address of principal executive offices)\n\n \n\n**403-637-0420**\n\n(Issuer’s Telephone Number)\n\n \n\n**Securities registered pursuant to Section 12(b) of the Act:**\n\n \n\n**None**\n\n \n\n**Securities registered pursuant to Section 12(g) of the Act:**\n\n \n\n**Title of each class**\n\n \n\n**Trading Symbol(s)**\n\n \n\n**Name of each exchange on which registered**\n\nN/A\n\n \n\nN/A\n\n \n\nN/A\n\n \n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes ☒     No ☐\n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒     No ☐\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one)\n\n \n\nLarge accelerated filer\n\n☐\n\nAccelerated filer\n\n☐\n\nNon-accelerated filer\n\n☒\n\nSmaller reporting company\n\n☒\n\nEmerging growth company\n\n☐\n\n \n\n \n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes     ☒ No\n\n \n\nThe number of shares of the registrant’s common shares issued and outstanding as of May 20, 2026, was 678,501,405 shares.\n\n \n\n \n\n \n\n \n\n**CANNAPHARMARX, INC.**\n\n**March 31, 2026**\n\n**TABLE OF CONTENTS**\n\n \n\n \n\n \n\n**Page**\n\n \n\n**PART I. FINANCIAL INFORMATION**\n\n \n\n \n\n \n\n \n\n[Item 1](#FS)\n\n[Condensed Interim Consolidated Financial Statements (unaudited)](#FS)\n\n3\n\n[Item 2](#P1I2)\n\n[Management’s Discussion and Analysis of Financial Condition and Results of Operations/Plan of Operation](#P1I2)\n\n18\n\n[Item 3](#P1I3)\n\n[Quantitative and Qualitative Disclosures About Market Risk](#P1I3)\n\n28\n\n[Item 4](#P1I4)\n\n[Controls and Procedures](#P1I4)\n\n28\n\n \n\n \n\n \n\n \n\n**PART II. OTHER INFORMATION**\n\n \n\n \n\n \n\n \n\n[Item 1](#P2I1)\n\n[Legal Proceedings](#P2I1)\n\n30\n\n[Item 1A](#P2I1A)\n\n[Risk Factors](#P2I1A)\n\n30\n\n[Item 2](#P2I2)\n\n[Unregistered Sales of Equity Securities and Use of Proceeds](#P2I2)\n\n30\n\n[Item 3](#P2I3)\n\n[Defaults Upon Senior Securities](#P2I3)\n\n30\n\n[Item 4](#P2I4)\n\n[Mine Safety Disclosures](#P2I4)\n\n30\n\n[Item 5](#P2I5)\n\n[Other Information](#P2I5)\n\n30\n\n[Item 6](#P2I6)\n\n[Exhibits](#P2I6)\n\n31\n\n \n\n[Signatures](#SIGN)\n\n32\n\n \n\n \n\n2\n\n*Table of Contents*\n\n \n\n**CANNAPHARMARX, INC.**\n\n**CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS**\n\n**(in United States dollars)**\n\n \n\n \n\n \n\n**March 31,**\n\n**2026**\n\n(Unaudited)\n\n \n\n \n\n**December 31,**\n\n**2025**\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n**ASSETS**\n\n \n\n \n\n \n\n \n\n \n\n \n\n**Current assets**\n\n \n\n \n\n \n\n \n\n \n\n \n\nCash\n\n \n**$****633**\n \n\n \n$1,804\n \n\nGoods and services tax receivable\n\n \n\n \n**19,064**\n \n\n \n\n \n29,832\n \n\nAccounts receivable\n\n \n\n \n**6,944**\n \n\n \n\n \n164,430\n \n\nInventory\n\n \n\n \n**902,913**\n \n\n \n\n \n1,115,322\n \n\nTotal current assets\n\n \n\n \n**929,554**\n \n\n \n\n \n1,311,388\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n**Non-current assets**\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nEquipment, net\n\n \n\n \n**176,101**\n \n\n \n\n \n127,029\n \n\nRight-of-use building, net\n\n \n\n \n**5,475,079**\n \n\n \n\n \n5,579,987\n \n\n**Total assets**\n\n \n**$****6,580,734**\n \n\n \n$7,018,404\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n**LIABILITIES AND SHAREHOLDERS’ DEFICIT**\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n**Current liabilities**\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nAccounts payable and accrued liabilities\n\n \n**$****10,232,578**\n \n\n \n$10,059,415\n \n\nAccrued interest\n\n \n\n \n**2,157,329**\n \n\n \n\n \n1,720,278\n \n\nDeferred revenue\n\n \n\n \n**-**\n \n\n \n\n \n260,561\n \n\nNotes payable\n\n \n\n \n**478,270**\n \n\n \n\n \n482,661\n \n\nConvertible notes\n\n \n\n \n**1,017,004**\n \n\n \n\n \n1,017,004\n \n\nDerivative conversion feature\n\n \n\n \n**1,208,438**\n \n\n \n\n \n2,009,476\n \n\nLoans payable to related parties, current portion\n\n \n\n \n**13,130,027**\n \n\n \n\n \n12,567,911\n \n\nRoyalty payable\n\n \n\n \n**429,520**\n \n\n \n\n \n305,492\n \n\nLiability for right-of-use building, current portion\n\n \n\n \n**983,755**\n \n\n \n\n \n1,000,479\n \n\nObligation to issue shares\n\n \n\n \n**1,849,155**\n \n\n \n\n \n2,166,681\n \n\nTotal current liabilities\n\n \n\n \n**31,486,076**\n \n\n \n\n \n31,589,958\n \n\n**Non-current liability**\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nLoans payable to related parties\n\n \n\n \n**433,696**\n \n\n \n\n \n548,574\n \n\nLiability for right-of-use building\n\n \n\n \n**4,930,850**\n \n\n \n\n \n5,033,601\n \n\n**Total liabilities**\n\n \n**$****36,850,622**\n \n\n \n$37,172,133\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n**SHAREHOLDERS’ DEFICIT**\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nPreferred shares series A, $1.00 par value, 100,000 shares authorized, 74,416 issued and outstanding as at March 31, 2026 and December 31, 2025\n\n \n**$****74,416**\n \n\n \n$74,416\n \n\nPreferred shares series B, $1.00 par value, 3,000,000 shares authorized, 455,000 shares issued and outstanding as at March 31, 2026 and December 31, 2025\n\n \n\n \n**455,000**\n \n\n \n\n \n455,000\n \n\nPreferred shares series C, $1.00 par value, 100,000 shares authorized, 100,000 shares issued and outstanding as at March 31, 2026 and December 31, 2025\n\n \n\n \n**100,000**\n \n\n \n\n \n100,000\n \n\nCommon shares, $0.0001 par value; 5,000,000,000 and 5,000,000,000 shares authorized, 678,501,405 and 662,501,405 issued and outstanding as at March 31, 2026 and December 31, 2025, respectively\n\n \n\n \n**67,850**\n \n\n \n\n \n66,250\n \n\nShares to be issued\n\n \n\n \n**-**\n \n\n \n\n \n1,600\n \n\nTreasury shares, $0.0001 par value 6,230,761 shares as at March 31, 2026 and December 31, 2025\n\n \n\n \n**623**\n \n\n \n\n \n623\n \n\nAdditional paid-in capital\n\n \n\n \n**81,520,643**\n \n\n \n\n \n81,520,643\n \n\nAccumulated deficit\n\n \n\n \n**(112,697,611****)**\n \n\n \n(112,315,590)\n\nAccumulated other comprehensive income\n\n \n\n \n**209,191**\n \n\n \n\n \n(56,671)\n\nTotal shareholders’ deficit\n\n \n\n \n**(30,269,888****)**\n \n\n \n(30,153,729)\n\n**Total liabilities and shareholders’ deficit**\n\n \n**$****6,580,734**\n \n\n \n$7,018,404\n \n\n \n\nThe accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.\n\n \n\n \n\n3\n\n*Table of Contents*\n\n \n\n**CANNAPHARMARX, INC.**\n\n**CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS**\n\n**For the three months ended March 31, 2026 and 2025**\n\n**(in United States dollars)**\n\n**(Unaudited)**\n\n \n\n \n\n \n\nThree months ended\n\nMarch 31,\n\n \n\n \n\n \n\n**2026**\n\n \n\n \n\n2025\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n**Revenue**\n\n \n**$****627,462**\n \n\n \n$335,319\n \n\n**Cost of goods sold**\n\n \n\n \n**1,036,915**\n \n\n \n\n \n837,926\n \n\n**Gross loss**\n\n \n\n \n**(409,453****)**\n \n\n \n(502,607)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n**Operating expenses**\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nGeneral and administrative\n\n \n\n \n**35,814**\n \n\n \n\n \n38,641\n \n\nProfessional fees\n\n \n\n \n**105,856**\n \n\n \n\n \n136,337\n \n\nRoyalty expense\n\n \n\n \n**131,220**\n \n\n \n\n \n-\n \n\nTotal operating expenses\n\n \n\n \n**272,890**\n \n\n \n\n \n174,978\n \n\nLoss from operations\n\n \n\n \n**(682,343****)**\n \n\n \n(677,585)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n**Other income (expenses)**\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nChange in the fair value of derivative conversion feature\n\n \n\n \n**801,038**\n \n\n \n\n \n641,711\n \n\nChange in the fair value of obligation to issue shares\n\n \n\n \n**317,527**\n \n\n \n\n \n1,880,911\n \n\nForeign exchange gain (loss)\n\n \n\n \n**(31,084****)**\n \n\n \n9,885\n \n\nInterest expense\n\n \n\n \n**(475,617****)**\n \n\n \n(615,516)\n\nImputed interest expense\n\n \n\n \n**(311,542****)**\n \n\n \n-\n \n\nOther expense\n\n \n\n \n**-**\n \n\n \n\n \n(1,930,000)\n\nTotal other income (expenses)\n\n \n\n \n**300,322**\n \n\n \n\n \n(13,009)\n\n**Net loss**\n\n \n\n \n**(382,021****)**\n \n\n \n(690,594)\n\nForeign currency translation adjustment\n\n \n\n \n**265,862**\n \n\n \n\n \n(6,891)\n\n**Net comprehensive loss**\n\n \n**$****(116,159****)**\n \n$(697,485)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nBasic and diluted income (loss) per share of common shares\n\n \n**$****(0.00****)**\n \n$(0.00)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n**Weighted average number of shares outstanding**\n\n \n\n \n**669,790,294**\n \n\n \n\n \n662,501,405\n \n\n \n\nThe accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.\n\n \n\n \n\n4\n\n*Table of Contents*\n\n \n\n**CANNAPHARMARX, INC.**\n\n**CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS**\n\n**For the three months ended March 31, 2026 and 2025**\n\n**(in United States dollars)**\n\n**(Unaudited)**\n\n \n\n \n\n \n\nThree months ended\n\nMarch 31,\n\n \n\n \n\n \n\n**2026**\n\n \n\n \n\n2025\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n**Operating activities**\n\n \n\n \n\n \n\n \n\n \n\n \n\nNet loss\n\n \n**$****(382,021****)**\n \n$(690,594)\n\nAdjustments for non-cash items:\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nAmortization and depreciation included in cost of goods sold\n\n \n\n \n\n  (15,808\n\n) \n\n \n\n \n\n (18,509\n\n) \n\nAmortization and depreciation\n\n \n\n \n\n15,808\n\n \n\n \n\n \n\n 18,509\n\n \n\nChange in the fair value of derivative conversion feature\n\n \n\n \n**(801,038****)**\n \n\n \n(641,711)\n\nChange in the fair value of obligation to issue shares\n\n \n\n \n**(317,527****)**\n \n\n \n(1,880,911)\n\nForeign exchange loss\n\n \n\n \n**31,084**\n \n\n \n\n \n-\n \n\nOther expense\n\n \n\n \n**-**\n \n\n \n\n \n1,930,000\n \n\nInterest expense\n\n \n\n \n**475,617**\n \n\n \n\n \n615,516\n \n\nImputed interest expense\n\n \n\n \n**311,542**\n \n\n \n\n \n-\n \n\nLoss on impairment of inventory included in cost of goods sold\n\n \n\n \n**493,722**\n \n\n \n\n \n479,933\n \n\nChanges in operating assets and liabilities:\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nGoods and services tax receivable\n\n \n\n \n**10,435**\n \n\n \n\n \n(2,786)\n\nAccounts receivable\n\n \n\n \n**(358,784****)**\n \n\n \n(261,129)\n\nInventory\n\n \n\n \n**(281,019****)**\n \n\n \n(416,310)\n\nDeferred revenue\n\n \n\n \n**(260,343****)**\n \n\n \n66,148\n \n\nRoyalty payable\n\n \n\n \n**131,220**\n \n\n \n\n \n-\n \n\nAccounts payable and accrued liabilities\n\n \n\n \n**703,456**\n \n\n \n\n \n200,463\n \n\n**Cash used in operating activities**\n\n \n\n \n**(243,656****)**\n \n\n \n(601,381)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n**Financing activities**\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nProceeds from related party loans\n\n \n\n \n**242,485**\n \n\n \n\n \n600,433\n \n\n**Cash provided by financing activities**\n\n \n\n \n**242,485**\n \n\n \n\n \n600,433\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nNet change in cash\n\n \n\n \n**(1,171****)**\n \n\n \n(948)\n\nCash, beginning of period\n\n \n\n \n**1,804**\n \n\n \n\n \n2,156\n \n\n**Cash, end of period**\n\n \n**$****633**\n \n\n \n$1,208\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n**Supplemental disclosure of cash flow information:**\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nCash paid for income taxes\n\n \n**$****-**\n \n\n \n$-\n \n\nCash paid for interest expense\n\n \n**$****-**\n \n\n \n$-\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n**Supplemental disclosure of non-cash financing and investing activities:**\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nCash received by related parties directly from customers\n\n \n**$****516,021**\n \n\n \n$-\n \n\nCash paid by related parties directly to suppliers\n\n \n**$****519,531**\n \n\n \n$-\n \n\nEquipment in accounts payable and accrued liabilities\n\n \n**$****55,118**\n \n\n \n$-\n \n\nReclassification of notes payable to loans payable to related parties\n\n \n**$****-**\n \n\n \n$6,809,386\n \n\n \n\nThe accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.\n\n \n\n \n\n5\n\n*Table of Contents*\n\n \n\n**CANNAPHARMARX, INC.**\n\n**CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT**\n\n**(in United States dollars)**\n\n**(Unaudited)**\n\n \n\n \n\n \n\n**Preferred Shares**\n\n \n\n \n\n**Preferred Shares**\n\n \n\n \n\n**Preferred Shares**\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n**Accumulated**\n\n \n\n \n\n \n\n \n\n \n\n \n\n**Series A**\n\n \n\n \n\n**Series B**\n\n \n\n \n\n**Series C**\n\n \n\n \n\n**Common Shares**\n\n \n\n \n\n**Shares to be issued**\n\n \n\n \n\n**Treasury Shares**\n\n \n\n \n\n**Additional**\n\n \n\n \n\n \n\n \n\n**Other**\n\n \n\n \n\n**Total**\n\n \n\n \n\n \n\n**Number**\n\n** **\n\n** **\n\n** **\n\n** **\n\n**Number**\n\n** **\n\n** **\n\n** **\n\n** **\n\n**Number**\n\n** **\n\n** **\n\n** **\n\n** **\n\n**Number**\n\n** **\n\n** **\n\n** **\n\n** **\n\n**Number**\n\n** **\n\n** **\n\n** **\n\n** **\n\n**Number**\n\n** **\n\n** **\n\n** **\n\n** **\n\n**Paid-in**\n\n** **\n\n** **\n\n**Accumulated**\n\n** **\n\n** **\n\n**Comprehensive**\n\n** **\n\n** **\n\n**Shareholders’**\n\n** **\n\n** **\n\n** **\n\n**of shares**\n\n** **\n\n** **\n\n**Value**\n\n** **\n\n** **\n\n**of shares**\n\n** **\n\n** **\n\n**Value**\n\n** **\n\n** **\n\n**of shares**\n\n** **\n\n** **\n\n**Value**\n\n** **\n\n** **\n\n**of shares**\n\n** **\n\n** **\n\n**Value**\n\n** **\n\n** **\n\n**of shares**\n\n** **\n\n** **\n\n**Value**\n\n** **\n\n** **\n\n**of shares**\n\n** **\n\n** **\n\n**Value**\n\n \n\n \n\n**Capital**\n\n \n\n \n\n**Deficit**\n\n \n\n \n\n**(Loss) Income**\n\n \n\n \n\n **Deficit**\n\n \n\nBalance, December 31, 2024\n\n \n\n \n74,416\n \n\n \n$74,416\n \n\n \n\n \n455,000\n \n\n \n$455,000\n \n\n \n\n \n100,000\n \n\n \n$100,000\n \n\n \n\n \n662,501,405\n \n\n \n$66,250\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n6,230,761\n \n\n \n$623\n \n\n \n$80,122,590\n \n\n \n$(101,184,142)\n \n$555,626\n \n\n \n$(19,809,637)\n\nChange in foreign currency translation\n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n(6,891)\n \n\n \n(6,891)\n\nNet loss\n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n(690,594)\n \n\n \n-\n \n\n \n\n \n(690,594)\n\nBalance, March 31, 2025\n\n \n\n \n74,416\n \n\n \n$74,416\n \n\n \n\n \n455,000\n \n\n \n$455,000\n \n\n \n\n \n100,000\n \n\n \n$100,000\n \n\n \n\n \n662,501,405\n \n\n \n$66,250\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n6,230,761\n \n\n \n$623\n \n\n \n$80,122,590\n \n\n \n$(101,874,736)\n \n$548,735\n \n\n \n$(20,507,122)\n\nRelated party loan modification, adjustment\n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n1,256,853\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n1,256,853\n \n\nShares to be issued\n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n16,000,000\n \n\n \n\n \n1,600\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n141,200\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n142,800\n \n\nChange in foreign currency translation\n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n(605,406)\n \n\n \n(605,406)\n\nNet loss\n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n(10,440,854)\n \n\n \n-\n \n\n \n\n \n(10,440,854)\n\nBalance, December 31, 2025\n\n \n\n \n74,416\n \n\n \n$74,416\n \n\n \n\n \n455,000\n \n\n \n$455,000\n \n\n \n\n \n100,000\n \n\n \n$100,000\n \n\n \n\n \n662,501,405\n \n\n \n$66,250\n \n\n \n\n \n16,000,000\n \n\n \n\n \n1,600\n \n\n \n\n \n6,230,761\n \n\n \n$623\n \n\n \n$81,520,643\n \n\n \n$(112,315,590)\n \n$(56,671)\n \n$(30,153,729)\n\nIssuance of common shares\n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n16,000,000\n \n\n \n\n \n1,600\n \n\n \n\n \n(16,000,000)\n \n\n \n(1,600)\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\nChange in foreign currency translation\n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n265,862\n \n\n \n\n \n265,862\n \n\nNet loss\n\n \n\n \n**-**\n \n\n \n\n \n**-**\n \n\n \n\n \n**-**\n \n\n \n\n \n**-**\n \n\n \n\n \n**-**\n \n\n \n\n \n**-**\n \n\n \n\n \n**-**\n \n\n \n\n \n**-**\n \n\n \n\n \n-\n \n\n \n\n \n-\n \n\n \n\n \n**-**\n \n\n \n\n \n**-**\n \n\n \n\n \n**-**\n \n\n \n\n \n(382,021)\n \n\n \n**-**\n \n\n \n\n \n(382,021)\n\n**Balance, March 31, 2026**\n\n \n\n \n**74,416**\n \n\n \n**$****74,416**\n \n\n \n\n \n**455,000**\n \n\n \n**$****455,000**\n \n\n \n\n \n**100,000**\n \n\n \n**$****100,000**\n \n\n \n\n \n**678,501,405**\n \n\n \n**$****67,850**\n \n\n \n\n \n**-**\n \n\n \n\n \n**-**\n \n\n \n\n \n**6,230,761**\n \n\n \n**$****623**\n \n\n \n**$****81,520,643**\n \n\n \n**$****(112,697,611****)**\n \n**$****209,191**\n \n\n \n**$****(30,269,888****)**\n\n \n\nThe accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.\n\n \n\n \n\n6\n\n*Table of Contents*\n\n \n\n**CANNAPHARMARX, INC.**\n\n**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**\n\n**FOR THE THREE ENDED MARCH 31, 2026 AND 2025**\n\n**(in United States dollars) **\n\n \n\n**NOTE 1 - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES**\n\n \n\nCannaPharmaRx, Inc. was originally incorporated in the state of Colorado in August 1998 as Network Acquisitions, Inc. The Company underwent several name changes over the years and, in October 2014, changed its legal name to CannaPharmaRx, Inc. (hereinafter the “Company”). The Company focuses its business efforts on the acquisition, development and operation of cannabis cultivation facilities in Canada.\n\n \n\nOn January 6, 2022, the Company entered into a 20-year operating lease with Formosa Mountain Ltd. (“Formosa”) for the use of a facility located in Cremona, Alberta, Canada. During 2022, the Company recommissioned the 55,000 square foot facility (the “Facility”) into an indoor cannabis farm with 10 growing rooms and one drying and packing room. During 2025, the Company added one additional growing room to its operations. The Facility now has six growing rooms and one drying and packing room in operation and plans to increase capacity over the next one to two years to open a second drying and packing room and to operate all 10 growing rooms.\n\n \n\nThe Company received an operating license from Health Canada on December 9, 2022, and a cannabis license from the Canada Revenue Agency on December 22, 2022, and commenced cannabis production during the year ended December 31, 2023. Our common shares are traded on the OTC Pink Sheets under the trading symbol “CPMD.”\n\n \n\n**Potential liability exposure and insurance coverage**\n\n \n\nThe Company has not paid any insurance premiums since early 2024. As a result, its current insurance coverage has lapsed. The Company may be subject to claims for damages and other expenses that are not covered by insurance. The Company’s business, profitability, and growth prospects could be adversely affected in the event it is required to pay damages and incur defense costs in connection with a liability claim. There can be no assurance that the Company will be able to reinstate or obtain insurance coverage in the future in amounts, or at a cost, that would provide adequate protection.\n\n \n\n**Basis of presentation**\n\n \n\nThe accompanying unaudited condensed interim consolidated financial statements (the “financial statements”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and applicable rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with US GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2025.\n\n \n\nAll figures are in United States (“US”) dollars (“USD”) unless indicated otherwise. All references to “CAD” are to Canadian dollars.\n\n \n\n**Foreign currency translation**\n\n \n\nAs at March 31, 2026, the official exchange rate for the translation of CAD to USD was 0.7174 (December 31, 2025 - 0.7296). During the three months ended March 31, 2026, the official average exchange rate for translation of CAD to USD was 0.7290 (2025 - 0.6968).\n\n \n\n**Loss per share**\n\n \n\nLoss per share is presented in accordance with Accounting Standards Update, Earnings per Share (Topic 260), which requires the presentation of both basic and diluted earnings per share (“EPS”) on the income statements.\n\n \n\nBasic EPS excludes any dilutive effects of share options, share purchase warrants, and convertible securities but does include the restricted shares of common shares issued. Basic EPS calculations are determined by dividing net income by the weighted average number of shares of common shares outstanding during the year.\n\n \n\nDiluted EPS reflects the potential dilution that would occur if securities or other contracts to issue common shares were exercised using the treasury stock method or converted to common shares using the if-converted method. Diluted EPS calculations are determined by dividing net income by the weighted average number of shares of common shares and dilutive common shares equivalents outstanding. Diluted EPS excludes all dilutive potential common shares if their effect is anti-dilutive. As of March 31, 2026, convertible preferred shares outstanding totaled 629,416 shares (December 31, 2025 - 629,416 shares) and share purchase warrants outstanding totaled 39,924,940 (December 31, 2025 - 39,924,940). The Company’s convertible notes were all excluded from the calculation of diluted EPS on the basis that they were anti-dilutive.\n\n \n\n***Fair values of assets and liabilities***\n\n** \n\nThe Company groups its financial assets and financial liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded, and the reliability of the assumptions used to determine fair value.\n\n \n\nLevel 1:\n\nValuation is based on quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities generally include debt and equity securities that are traded in an active exchange market. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.\n\n \n\n \n\nLevel 2:\n\nValuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For example, Level 2 assets and liabilities may include debt securities with quoted prices that are traded less frequently than exchange-traded instruments.\n\n \n\n \n\nLevel 3:\n\nValuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. This category generally includes certain private equity investments and long-term derivative contracts.\n\n \n\nThe fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.\n\n \n\nThe Company’s financial assets and liabilities comprise of cash, accounts receivable, accounts payable and accrued liabilities, accrued interest, notes payable, convertible notes, derivative conversion feature, loans payable to related parties, royalty payable and obligation to issue shares. \n\n \n\nThe Company measures the fair value of its convertible notes, derivative conversion feature and obligation to issue shares based on Level 3 hierarchy.\n\n \n\nThere are no other financial assets or liabilities measured at fair value on a recurring basis presented on the Company’s balance sheet. As at March 31, 2026, the carrying values of the Company’s financial instruments approximate their fair values. \n\n \n\n**Use of estimates**\n\n \n\nThe preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates relate to the impairment of long-lived assets, the valuation of financial instruments, the valuation of inventory, the provision of income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as at the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.\n\n \n\nIn preparing these financial statements, the Company is exposed to the same sources of estimation uncertainty as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025\n\n \n\n \n\n \n\n7\n\n*Table of Contents*\n\n \n\n**CANNAPHARMARX, INC.**\n\n**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**\n\n**FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025**\n\n**(in United States dollars)**\n\n \n\n**NOTE 1 - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (continued)**\n\n  \n\n**** \n\n**Reclassification of prior period amounts**\n\n \n\nRent expense for the three months ended March 31, 2025 of $1,045 has been reclassified to general and administrative expenses, and foreign exchange gain for the three months ended March 31, 2025 of $9,885 has been reclassified from general and administrative expenses and presented within other income. These reclassifications had no impact on the Company’s loss from operations or net comprehensive loss for any period presented.\n\n \n\n**Significant Accounting Policies**\n\n \n\nThere have been no material changes to our significant accounting policies from our Annual Report on Form 10-K for the year ended December 31, 2025.\n\n \n\n**NOTE 2 - GOING CONCERN AND LIQUIDITY**\n\n \n\nAs at March 31, 2026, the Company had cash of $633 (December 31, 2025 - $1,804), a working capital deficiency of $30,556,522 (December 31, 2025 - $30,278,570) and an accumulated deficit of $112,697,611 (December 31, 2025 - $112,315,590). Additionally, during the three months ended March 31, 2026, the cash used in operating activities was $243,656 (2025 - $601,381).\n\n \n\nThese financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.\n\n \n\nBased on current financial projections, the Company does not have sufficient existing cash resources to fund its current operations. Accordingly, there is substantial doubt about the Company’s ability to continue as a going concern. Management intends to address these liquidity challenges through debt financings and/or raise additional funding through equity financing to support ongoing operating expenses and working capital needs. There is no assurance that these events will be satisfactorily completed or at terms acceptable to the Company and therefore, the Company is heavily reliant on funding from related parties. If the Company is unable to secure adequate financing or otherwise successfully implement its plans, it may be required to significantly reduce or curtail its operations, or cease operations entirely. Any issuance of equity securities to raise capital could result in substantial dilution to existing shareholders. Certain borrowings are secured by the Company’s assets, including equipment, investments and receivables. In the event of default, lenders may have the right to seize collateralized assets. These consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.\n\n \n\nOn March 17, 2025, the Company and its subsidiary, 2323414 Alberta Ltd. (“Alberta Ltd.”), which operates the Company’s principal business activities, including the cultivation, processing, and distribution of cannabis, entered into a security and royalty agreement with Koze Investments LLC (“Koze”), a California-based limited liability company engaged in providing financing and investment services. Alberta Ltd. is a subsidiary of the Company in which Koze has been considered a related party since March 11, 2025, the date on which its manager, Elliot Zemel, was appointed as a director of the Company. Pursuant to the agreement, the Company is required to pay a royalty on cannabis product sales from the prior month. If royalty payments are not made on time, the applicable rate increases. The agreement stipulates that a default occurs if Alberta Ltd. fails to make royalty or lease payments for three consecutive months, or for any four months within a rolling six-month period. As collateral, the Company granted Koze a security interest in its entire ownership interest in Alberta Ltd., which will remain in place until all obligations are fully satisfied. As of March 31, 2026, Alberta Ltd. was in default of its payment obligations, and Koze agreed to forbear from exercising his rights over the ownership interest until May 31, 2026. The Company also incurred royalty expenses under the agreement and recorded a related liability in accounts payable and accrued liabilities as of March 31, 2026.\n\n \n\n \n\n8\n\n*Table of Contents*\n\n \n\n**CANNAPHARMARX, INC.**\n\n**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**\n\n**FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025**\n\n**(in United States dollars)**\n\n \n\n**NOTE 3 - INVENTORY**\n\n \n\nA summary of the Company’s inventory as at March 31, 2026 and December 31, 2025 is as follows:\n\n \n\n \n\n \n\n**2026**\n\n \n\n \n\n2025\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFinished goods, net of impairment provision from prior periods\n\n \n**$****741,495**\n \n\n \n$827,537\n \n\nWork in process, net of impairment provision from prior periods\n\n \n\n \n**647,292**\n \n\n \n\n \n774,265\n \n\nLess: impairment of work in process inventory included in cost of goods sold\n\n \n\n \n**(485,874****)**\n \n\n \n(486,480)\n\n \n\n \n**$****902,913**\n \n\n \n$1,115,322\n \n\n \n\nThe Company evaluates its inventory, including work in progress, at each reporting period to ensure it is stated at the lower of cost or net realizable value (“NRV”). NRV is defined as the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal, and transportation.\n\n \n\nIf the estimated NRV of inventory is less than its recorded cost, the Company records a write-down to reflect the inventory at NRV. Such write-downs are recognized in cost of goods sold in the period identified.\n\n \n\n**NOTE 4 - DERIVATIVE CONVERSION FEATURE**\n\n \n\nA summary of Company’s derivative conversion feature which arises from convertible notes as at March 31, 2026 is as follows:\n\n \n\nBalance, December 31, 2024\n\n \n$1,159,324\n \n\nChanges in fair value of derivative conversion feature\n\n \n\n \n850,152\n \n\nBalance, December 31, 2025\n\n \n\n \n2,009,476\n \n\nChanges in fair value of derivative conversion feature\n\n \n\n \n(801,038)\n\n**Balance, March 31, 2026**\n\n \n**$****1,208,438**\n \n\n \n\nThe Company used an option pricing model to calculate the derivative conversion feature. A summary of the Company’s weighted average inputs used in the model for the three months ended March 31, 2026 and the year ended December 31, 2025 is as follows:\n\n \n\n \n\n \n\n**Period ended March 31, 2026**\n\n \n\n \n\nYear ended December 31, 2025\n\n \n\nShare price\n\n \n**$****0.004**\n \n\n \n$0.005\n \n\nExercise price\n\n \n**$****0.003**\n \n\n \n$0.002\n \n\nRisk-free interest rate\n\n \n\n \n**3.00****%**\n \n\n \n2.90%\n\nExpected volatility\n\n \n\n \n**352.40****%**\n \n\n \n348.80%\n\nExpected life\n\n \n\n**1.00****year**\n\n \n\n \n\n1.00 year\n\n \n\nExpected dividend yield\n\n \n\n \n**0.00****%**\n \n\n \n0.00%\n\n \n\nThe risk-free interest rate was based on rates established by the Federal Reserve Bank. Beginning with the year ended December 31, 2025, the Company estimated expected volatility using a peer‑based approach rather than the historical volatility of its own common shares. The Company’s common shares trade infrequently on the OTC Markets, and management determined that historical volatility derived solely from Company‑specific trading data was not reflective of market‑participant assumptions. As at the date of these financial statements, all convertible notes were past their maturity date and accordingly, the expected term of the conversion feature of the notes was assumed to be 1 year from the date of these financial statements. The expected annual dividend yield was based on the fact that the Company has not customarily paid dividends in the past and does not expect to pay dividends in the future.\n\n \n\n \n\n9\n\n*Table of Contents*\n\n \n\n**CANNAPHARMARX, INC.**\n\n**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**\n\n**FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025**\n\n**(in United States dollars)**\n\n \n\n**NOTE 5 - RELATED PARTY TRANSACTIONS**\n\n \n\nA related party is any individual or entity that can exercise significant influence over the Company, or over which the Company can exercise significant influence. Related parties include affiliates, principal owners, directors, executive management, their immediate family members, and entities under common control. The Company has a significant amount of related party balances and transactions.\n\n \n\na) Key related party transactions\n\n \n\nA summary of the Company’s related party transactions is as follows:\n\n \n\n \n\n \n\nThree months ended\n\nMarch 31,\n\n \n\n \n\n \n\n**2026**\n\n \n\n \n\n2025\n\n \n\n \n\n \n\n**$ **\n\n \n\n \n\n$\n\n \n\nRevenue\n\n \n\n \n**627,462**\n \n\n \n\n \n-\n \n\nLease expense due to Formosa included in cost of goods sold\n\n \n\n \n**273,374**\n \n\n \n\n \n261,285\n \n\nProfessional fees\n\n \n\n \n**53,758**\n \n\n \n\n \n112,363\n \n\nRoyalty expense\n\n \n\n \n**131,220**\n \n\n \n\n \n-\n \n\nInterest expense\n\n \n\n \n**360,188**\n \n\n \n\n \n585,063\n \n\nImputed interest expense\n\n \n\n \n**311,542**\n \n\n \n\n \n-\n \n\nOther expense\n\n \n\n \n**-**\n \n\n \n\n \n1,930,000\n \n\n \n\n*Revenue*\n\n \n\nDuring the three months ended March 31, 2026, the Company recognized all of its revenue of $627,462 (2025 - $nil) from related parties being D.N.S. CANTEK 2019 LTD (“Cantek”), an Israeli limited corporation owned 100% by Koze, and for which Mr. Tal serves as a financial advisor.\n\n \n\n*Lease expense*\n\n \n\nThe Company has a lease with Formosa, which became a related party upon the appointment of its manager, Elliot Zemel, as a director of the Company on March 11, 2025. During the three months ended March 31, 2026, the Company recognized interest expense related to rent in default of $161,323 (2025 - $154,702), associated with unpaid lease payments.\n\n \n\nDuring the three months ended March 31, 2026, the Company incurred lease expense of $273,374 (2025 - $261,285) associated with the Formosa lease, which is included in cost of goods sold.\n\n \n\n*Professional fees*\n\n \n\n \n\n·\nDuring the three months ended March 31, 2026, the Company incurred professional expenses of $42,733 (2025 - $78,363) related to accounting fees payable to Invictus Accounting Group LLP (“Invictus”), a company which provides part-time CFO, financial reporting, and bookkeeping services to the Company. Mr. Oliver Foeste is the Managing Partner of Invictus.\n\n \n\n·\nDuring the three months ended March 31, 2026, the Company incurred professional expenses of $11,025 payable to Fabian Vancott (2025 - $34,000) related to legal fees. Anthony Panek who is a partner in Fabian Vancott, is also a director of the Company.\n\n \n\n*Royalty expense*\n\n \n\nOn March 17, 2025, the Company and Alberta Ltd., entered into a security and royalty agreement with Koze (the “Royalty Agreement”) (Note 2), pursuant to which the Company is required to pay a royalty of CAD $0.20 per gram on cannabis product sales, payable at the beginning of the month for the previous month, as additional consideration related to the lease with Formosa. Immediately upon failure to pay the royalty when due, the royalty rate increases to CAD $0.40 per gram sold for the applicable month. As of March 31, 2026, Alberta Ltd. was in default of its payment obligations, and Koze agreed to forbear from exercising its rights over the ownership interest until May 31, 2026.\n\n \n\n \n\n10\n\n*Table of Contents*\n\n \n\n**CANNAPHARMARX, INC.**\n\n**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**\n\n**FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025**\n\n**(in United States dollars)**\n\n \n\n**NOTE 5 - RELATED PARTY TRANSACTIONS (continued)**\n\n** \n\n \n\nDuring the three months ended March 31, 2026, the Company sold 450,000 grams of cannabis products, and for the three months ended March 31, 2026, the Company incurred a royalty expense of $131,220 (2025 - $nil).\n\n \n\n*Interest expense*\n\n \n\n \n\n·\nDuring the three months ended March 31, 2026, the Company incurred interest expense on promissory and convertible notes with Mr. Tal of $11,153 (2025 - $14,425).\n\n \n\n·\nDuring the three months ended March 31, 2026, the Company incurred interest expense on promissory and convertible notes with Koze of $160,108 (2025 - $415,936).\n\n \n\n·\nDuring the three months ended March 31, 2026, the Company incurred interest expense on promissory note with Formosa of $27,604 (2025 - $nil).\n\n \n\n·\nDuring the three months ended March 31, 2026, the Company incurred interest expense on rent in default with Formosa of $161,323 (2025 - $154,702).\n\n \n\n*Imputed interest expense*\n\n \n\n \n\n·\nDuring the three months ended March 31, 2026, the Company incurred imputed interest expense on promissory and convertible notes with Mr. Tal of $17,099 (2025 - $nil).\n\n \n\n·\nDuring the three months ended March 31, 2026, the Company incurred imputed interest expense on promissory and convertible notes with Koze of $248,108 (2025 - $nil)\n\n \n\n·\nDuring the three months ended March 31, 2026, the Company incurred imputed interest expense on promissory and convertible notes with Formosa of $46,335 (2025- $nil).\n\n \n\n*Other expense*\n\n \n\nDuring the three months ended March 31, 2025, the Company made a non-cash one-time adjustment of $1,930,000 to lease-related rent expense due to a clarification in the interpretation of the lease terms for the Facility, which is recorded as other expense.\n\n \n\nb) Amounts due to related parties\n\n \n\nA summary of the Company’s related party liabilities as at March 31, 2026 and December 31, 2025, is as follows: \n\n \n\n \n\n \n\n**2026**\n\n \n\n \n\n2025\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nAccounts payable and accrued liabilities\n\n \n**$****5,609,993**\n \n\n \n$5,416,889\n \n\nAccrued interest\n\n \n\n \n**1,675,619**\n \n\n \n\n \n1,352,899\n \n\nLoans payable to related parties\n\n \n\n \n**13,563,723**\n \n\n \n\n \n13,116,485\n \n\nRoyalty payable\n\n \n\n \n**429,520**\n \n\n \n\n \n305,492\n \n\nLiability for right-of-use building\n\n \n\n \n**5,914,605**\n \n\n \n\n \n6,034,080\n \n\nObligation to issue shares\n\n \n\n \n**1,849,155**\n \n\n \n\n \n2,166,681\n \n\n**Total related party liabilities**\n\n \n**$****29,042,615**\n \n\n \n$28,392,526\n \n\n  \n\n*Accounts payable and accrued liabilities*\n\n \n\nAs at March 31, 2026, accounts payable and accrued liabilities include balances owing to related parties as follows:\n\n \n\n \n\n·\nAs at March 31, 2026, $4,481,131 (December 31, 2025 - $4,283,706) was payable to Formosa for outstanding lease payments. As at March 31, 2026, accrued interest on unpaid lease payments on the Formosa lease was $1,178,602 (December 31, 2025 - $1,037,180).\n\n \n\n·\nAs at March 31, 2026, $141,896 (December 31, 2025 - $146,306) was payable to Invictus for part-time CFO, financial reporting, and bookkeeping services provided to the Company.\n\n \n\n·\nAs at March 31, 2026, $319,279 (December 31, 2025 - $319,279) was payable to Mr. Orman for unpaid directors’ fees for 2021 through 2023.\n\n \n\n \n\n11\n\n*Table of Contents*\n\n \n\n**CANNAPHARMARX, INC.**\n\n**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**\n\n**FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025**\n\n**(in United States dollars)**\n\n \n\n**NOTE 5 - RELATED PARTY TRANSACTIONS (continued)**\n\n \n\n \n\n·\nAs at March 31, 2026, $542,727 (December 31, 2025 - $551,953) was payable to Dominic Colvin, a director of the Company, for unpaid salary and expense reimbursement amounts during Mr. Colvin’s employment with the Company as its CEO during the years 2019 through 2022. Mr. Colvin has disputed this amount and is asserting a claim for $1,679,060. As of March 31, 2026, the Company is in the process of reviewing the claim and remains in ongoing discussions with Mr. Colvin. No resolution has been reached with respect to this matter.\n\n \n\n·\nAs at March 31, 2026, $124,960 (December 31, 2025 - $115,645) was payable to Fabian Vancott in respect of unpaid legal fees.\n\n \n\n*Loans payable to related parties*\n\n \n\nOn August 7, 2025, the Company entered into an agreement (the “Debt Modification”) with Mr. Tal, Koze and Formosa to amend the annual interest rates on all outstanding promissory and convertible notes held by them to 6%, compounding annually. This was deemed to be a substantial modification of the terms of the agreements and was accounted for as an extinguishment of the promissory and convertible notes and recognition of new notes at the new 6% rate. The term to maturity was unchanged. In connection with the issuance of the new notes resulting from the Debt Modification, the Company determined that the market interest rate for similar instruments was 15%. Accordingly, the debt was recorded at a discount to reflect this effective interest rate, with the discount amortized to imputed interest expense over the term of the debt using the effective interest method.\n\n \n\nAs at March 31, 2026, the loans payable to related parties consists of the following:\n\n \n\nPLC International Investments Inc. (“PLC”)\n\n \n\n \n\n·\n\nA $13,223 interest-free loan from PLC, a company owned by Dominic Colvin, a director of the Company;\n\n \n\nLoans payable to Koze\n\n \n\nOn March 11, 2025, Koze became a related party upon the appointment of its manager as a director of the Company. As a result, the balance owing on promissory notes was reclassified from notes payable to loans payable to related parties during the year ended December 31, 2025.\n\n \n\nOn August 7, 2025, the Company entered into the Debt Modification agreement with Koze to amend the annual interest rates on all outstanding promissory and convertible notes held by Koze to 6%, compounding annually.\n\n \n\n \n\n·\n*Koze Lucky Tackle Box Management, LLC (“LTB”):*\n\n \n\n \n\n \n\n \n\n \n\nOn November 22, 2023, the Company entered into promissory notes of $2,550,000 with Koze, as part of the LTB transaction, bearing interest at 13% per annum. Originally due on November 22, 2024, the maturity date for this note was extended to December 31, 2025, by agreement with Koze. On March 18, 2026, Mr. Tal and Koze agreed to extend the maturity date of the promissory notes to December 31, 2026.\n\n \n\n \n\n \nAs a result of the Debt Modification, principal and accrued interest outstanding related to the note as of August 7, 2025 of $2,550,000 and $555,406, respectively, were extinguished. A new note (“Koze LTB”) of $2,978,661 bearing 6% interest, compounding annually, was recognized resulting in a gain of $126,745 from extinguishment, recorded directly to additional paid-in capital.\n\n \n\n \n\n \n\n \n\n \nDuring the three months ended March 31, 2026, the Company recognized interest expense of $46,107 and imputed interest expense of $69,601 related to the note. As at March 31, 2026, the outstanding principal balance on the note was $3,163,079 (December 31, 2025 - $3,093,478) and accrued interest payable on the note was $122,169 (December 31, 2025 - $76,062).\n\n \n\n \n\n \n\n \n\n·\n*Koze A:*\n\n \n\n \n\n \n\n \n\n \nOn May 25, 2023, the Company entered into a promissory note with Koze, bearing annual interest at 24% compounded monthly, to fund for certain documented expenses.\n\n \n\n \n\n12\n\n*Table of Contents*\n\n \n\n**CANNAPHARMARX, INC.**\n\n**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**\n\n**FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025**\n\n**(in United States dollars)**\n\n \n\n**NOTE 5 - RELATED PARTY TRANSACTIONS (continued)**\n\n \n\n \n\n \n\n \n\nAs a result of the Debt Modification, principal and accrued interest outstanding related to the note as of August 7, 2025 of $849,278 and $443,339, respectively, were extinguished. A new note (“Koze A”) of $1,134,669 bearing 6% interest, compounding annually, was recognized resulting in a gain of $157,949 from extinguishment, recorded directly to additional paid-in capital.\n\n \n\n \n\n \n\n \n\n \nDuring the three months ended March 31, 2026, the Company recognized interest expense of $22,026 and imputed interest expense of $34,489 related to the note. During the three months ended March 31, 2026, the Company had $161,813 in net additions to the promissory note. As at March 31, 2026, the outstanding principal balance on the note was $1,596,545 (December 31, 2025 - $1,400,243) and accrued interest payable on the note was $53,096 (December 31, 2025 - $31,070).\n\n \n\n \n\n \n\n \n\n·\n*Koze B:*\n\n \n\n \n\n \n\n \n\n \nOn May 25, 2023, the Company entered into another promissory note with Koze, bearing annual interest at 24% compounded monthly, to fund the Company for certain documented expenses.\n\n \n\n \n\n \n\n \n\n \nAs a result of the Debt Modification, principal and accrued interest outstanding related to the note as of August 7, 2025 of $4,040,474 and $1,366,780, respectively, were extinguished. A new note (“Koze B”) of $4,767,106 bearing 6% interest, compounding annually, was recognized resulting in a gain of $640,148 from extinguishment, recorded directly to additional paid-in capital.\n\n \n\n \n\n \n\n \n\n \nDuring the three months ended March 31, 2026, the Company recognized interest expense of $84,794 and imputed interest expense of $132,769 related to the note. During the three months ended March 31, 2026, the Company made $84,182 in net repayments on the promissory note. As at March 31, 2026, the outstanding principal balance on the note was $5,652,377 (December 31, 2025 - $5,529,686) and accrued interest payable on the note was $213,594 (December 31, 2025 - $132,215).\n\n \n\n \n\n \n\n \n\n·\n*Koze C:*\n\n \n\n \n\n \n\n \n\n \nOn February 8, 2024, the Company entered into another promissory note with Koze, bearing annual interest at 24% compounded monthly.\n\n \n\n \n\n \n\n \n\n \nAs a result of the Debt Modification, principal and accrued interest outstanding related to the note as of August 7, 2025 of $275,000 and $97,403, respectively, were extinguished. A new note (“Koze C”) of $330,551 bearing 6% interest, compounding annually, was recognized resulting in a gain of $41,852 from extinguishment, recorded directly to additional paid-in capital.\n\n \n\n \n\n \n\n \n\n \nDuring the three months ended March 31, 2026, the Company recognized interest expense of $5,196 and imputed interest expense of $8,140 related to the note. As at March 31, 2026, the outstanding principal balance on the note was $351,841 (December 31, 2025 - $343,701) and accrued interest payable on the note was $13,590 (December 31, 2025 - $8,394).\n\n \n\n \n\n·\n*Koze convertible note (“Koze CN”):*\n\n \n\n \n\n \n\n \n\n \nThe Company has a convertible note with Koze, bearing annual interest at 24%.\n\n \n\n \n\n \n\n \n\n \nAs a result of the Debt Modification, principal and accrued interest outstanding related to the note as of August 7, 2025 of $68,555 and $75,714, respectively, were extinguished. A new note, Koze CN, of $126,275 bearing 6% interest, compounding annually, was recognized resulting in a gain of $17,995 from extinguishment, recorded directly to additional paid-in capital.\n\n \n\n \n\n \n\n \n\n \nDuring the three months ended March 31, 2026, the Company recognized interest expense of $1,985 and imputed interest expense of $3,109 related to the note. As at March 31, 2026, the outstanding principal balance on the note was $134,407 (December 31, 2025 - $131,298) and accrued interest payable on the note was $5,192 (December 31, 2025 - $3,207).\n\n \n\n \n\n13\n\n*Table of Contents*\n\n \n\n**CANNAPHARMARX, INC.**\n\n**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**\n\n**FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025**\n\n**(in United States dollars)**\n\n \n\n**NOTE 5 - RELATED PARTY TRANSACTIONS (continued)**\n\n \n\n \n\nDuring the three months ended March 31, 2026, Koze made payments of $519,531 directly to the Company’s suppliers. In addition, $516,021 was received directly by Koze, as collections from customers.\n\n \n\nLoans payable to Mr. Tal\n\n \n\nOn August 7, 2025, the Company entered into the Debt Modification agreement with Mr. Tal to amend the annual interest rates on all outstanding promissory and convertible notes held by him to 6%, compounding annually.\n\n \n\n \n\n·\n*Mr. Tal LTB:*\n\n \n\n \n\n \n\n \n\n \nOn November 22, 2023, the Company entered into a promissory note of $450,000 with Mr. Tal as part of the LTB transaction, bearing interest at 13% per annum. Originally due on November 22, 2024, the maturity date for this note was extended to December 31, 2025, by agreement with Mr. Tal. On March 18, 2026, Mr. Tal and Koze agreed to extend the maturity date of the promissory notes to December 31, 2026.\n\n \n\n \n\n \n\n \n\n \nAs a result of the Debt Modification, principal and accrued interest outstanding related to the note as of August 7, 2025 of $438,296 and $89,768, respectively, were extinguished. A new note (“Mr. Tal LTB”) of $507,422 bearing 6% interest, compounding annually, was recognized resulting in a gain of $20,641 from extinguishment, recorded directly to additional paid-in capital.\n\n \n\n \n\n \n\n \n\n \nDuring the three months ended March 31, 2026, the Company recognized interest expense of $6,518 and imputed interest expense of $9,844 related to the note. During the three months ended March 31, 2026, the Company made net repayments of $30,000 on the promissory note and accrued interest. As at March 31, 2026, the outstanding principal balance on the note was $441,659 (December 31, 2025 - $447,647) and accrued interest payable on the note was $4,237 (December 31, 2025 - $11,887).\n\n \n\n \n\n \n\n \n\n·\n*Mr. Tal convertible note (“Mr. Tal CN”):*\n\n \n\n \n\n \n\n \n\n \nThe Company had a convertible note with Mr. Tal, bearing interest at 24%.\n\n \n\n \n\n \n\n \n\n \nAs a result of the Debt Modification, principal and accrued interest outstanding related to the note as of August 7, 2025 of $212,555 and $121,427, respectively, were extinguished. A new note, Mr. Tal CN, of $294,850 bearing 6% interest, compounding annually, was recognized resulting in a gain of $39,132 from extinguishment, recorded directly to additional paid-in capital.\n\n \n\n \n\n \n\n \n\n \nDuring the three months ended March 31, 2026, the Company recognized interest expense of $4,635 and imputed interest expense of $7,255 related to the note. As at March 31, 2026, the outstanding principal balance on the note was $313,826 (December 31, 2025 - $306,571) and accrued interest payable on the note was $12,128 (December 31, 2025 - $7,488).\n\n \n\nPromissory note with Formosa\n\n \n\nOn January 1, 2025, the Company entered into a promissory note with Formosa in the amount of $1,930,000, bearing interest at 5% per annum, with respect to a one-time adjustment made to lease-related rent expense due to a clarification in the interpretation of the lease terms for the Facility.\n\n \n\nAs a result of the Debt Modification, principal and accrued interest outstanding related to the note as of August 7, 2025 of $1,930,000 and $58,098, respectively, were extinguished. A new note of $1,775,707 bearing 6% interest, compounding annually, was recognized resulting in a gain of $212,391 from extinguishment, recorded directly to additional paid-in capital.\n\n \n\nDuring the three months ended March 31, 2026, the Company recognized interest expense of $27,604 and imputed interest expense of $46,335 related to the note. As at March 31, 2026, the outstanding balance on the note was $1,896,766 (December 31, 2025 - $1,850,431) and accrued interest payable on the note was $73,012 (December 31, 2025 - $45,396).\n\n \n\n \n\n14\n\n*Table of Contents*\n\n \n\n**CANNAPHARMARX, INC.**\n\n**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**\n\n**FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025**\n\n**(in United States dollars)**\n\n \n\n**NOTE 5 - RELATED PARTY TRANSACTIONS (continued)**\n\n  \n\n \n\nA summary of the accrued interest of the Company’s loans payable to related parties as at March 31, 2026 and December 31, 2025 is as follows:\n\n \n\n \n\n \n\n**2026**\n\n \n\n \n\n2025\n\n \n\nKoze LTB\n\n \n**$****122,169**\n \n\n \n$76,062\n \n\nKoze A\n\n \n\n \n**53,096**\n \n\n \n\n \n31,070\n \n\nKoze B\n\n \n\n \n**213,594**\n \n\n \n\n \n132,215\n \n\nKoze C\n\n \n\n \n**13,590**\n \n\n \n\n \n8,394\n \n\nKoze CN\n\n \n\n \n**5,192**\n \n\n \n\n \n3,207\n \n\nMr. Tal LTB\n\n \n\n \n**4,237**\n \n\n \n\n \n11,887\n \n\nMr. Tal CN\n\n \n\n \n**12,128**\n \n\n \n\n \n7,488\n \n\nPromissory note with Formosa\n\n \n\n \n**73,012**\n \n\n \n\n \n45,396\n \n\n \n\n \n**$****497,018**\n \n\n \n$315,719\n \n\n \n\n*Royalty payable*\n\n \n\nPursuant to the Royalty Agreement, as of March 31, 2026, the royalty amount payable to Koze was $429,520 (CAD $598,708) (2025 - $nil).\n\n \n\n*Obligation to issue shares*\n\n \n\nAs at March 31, 2026, the Company has an obligation to issue an additional 172,015 Class C preferred shares to each of Mr. Tal and Koze (December 31, 2025 - 166,668 each) as part of the LTB transaction, valued at $924,578 for each party (December 31, 2025 - $1,083,341 each).\n\n \n\n*Liability for right-of-use building*\n\n \n\nOn March 11, 2025, Formosa became a related party upon the appointment of its manager as a director of the Company.\n\n \n\nAs at March 31, 2026, the liability for right-of-use building was $5,914,605 (December 31, 2025 - $6,034,080).\n\n \n\nUnder the terms of the agreement, a default occurs if Alberta Ltd. fails to make such payments or lease payments for three consecutive months or for any four months within any rolling six-month period. As collateral for the obligations under the agreement, the Company granted Koze a security interest in all of its ownership interest in Alberta Ltd. the security interest will remain in place until all obligations are fully satisfied. As of March 31, 2026, Alberta Ltd. has failed to make the payments under the agreement and Koze agreed to forbear from exercising his right of ownership interest in Alberta Ltd. until May 31, 2026 (Note 2).\n\n \n\n**NOTE 6 - COMMITMENTS, CONTINGENCIES AND LEGAL MATTERS**\n\n \n\nAs at March 31, 2026, the Company has outstanding borrowings under various loan agreements with multiple lenders, most of which are in default. Certain borrowings are secured by the Company’s assets, including equipment, investments and receivables. In the event of default, lenders may have the right to seize collateralized assets.\n\n \n\n**Steven Barber**\n\n \n\nAs part of the Company’s acquisition of Alternative Medical Solutions Inc. (“AMS”) in 2018, the Company is currently reviewing with legal counsel to ascertain whether it has claims against Steven Barber arising out of his default of the consulting agreement the Company entered into as part of the AMS acquisition (the “Consulting Agreement”). In January 2020, the Company received correspondence from counsel for Mr. Barber demanding payment on amounts purported to be due pursuant to his Consulting Agreement with the Company. The Company has reviewed whether Mr. Barber has performed pursuant to the terms of the Consulting Agreement and noticed concerns. \n\n \n\n \n\n15\n\n*Table of Contents*\n\n \n\n**CANNAPHARMARX, INC.**\n\n**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**\n\n**FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025**\n\n**(in United States dollars)**\n\n \n\n**NOTE 6 - COMMITMENTS, CONTINGENCIES AND LEGAL MATTERS (continued)**\n\n \n\n \n\nNo decision on whether to proceed on either of these situations has been reached as at the date of this Report, but the Company does not believe that these situations present a probability of material risk. As of March 31, 2026, the Company has an outstanding payable of $549,780 included in accounts payable and accrued liabilities (December 31, 2025 - $549,780).\n\n \n\n**Deloitte LLP**\n\n \n\nOn July 18, 2024, Deloitte LLP (“Deloitte”) filed a civil claim in the Alberta Court of Justice, alleging a breach of contract. Deloitte was engaged by the Company to assist with fiscal year 2022 finance backfill and diagnostic services and in accordance with a signed engagement letter dated August 29, 2022, proceeded to perform the professional services. Deloitte pleads that it has discharged its responsibilities and delivered its accounts to the Company. The Company acknowledged the satisfactory completion of services and the debts rendered but made no further payment as agreed other than an instalment payment on April 18, 2024. Deloitte is seeking recovery of the amount owed. As of March 31, 2026, the amount payable for services from Deloitte included in accounts payable and accrued liabilities was $33,953 (December 31, 2025 - $34,530).\n\n \n\n**Former Executives**\n\n \n\nFormer executives John Cassels and Andrew Steedman (collectively the “plaintiffs”) have filed a lawsuit against the Company alleging wrongful termination, related misconduct, and unpaid compensation. The plaintiffs seek $3 million in compensatory damages and an additional $3 million in punitive damages. During the three months ended March 31, 2026, the Company had a deposition related to the lawsuit which did not result in any material change to the status of the lawsuit. As of March 31, 2026, the Company maintains an accrual of approximately $916,000 for unpaid salaries owed to the plaintiffs for services rendered from April 2019 through June 2023. No additional loss contingency has been recorded, as the lawsuit remains in its early stages and the ultimate outcome is uncertain. The Company actively monitors this matter and will update its assessment as additional information becomes available.\n\n \n\n**Astor Street LLC**\n\n \n\nAstor Street LLC was issued two promissory notes by the Company in January 2021 and granted a security interest in all present and after acquired assets of the Company. Astor Street LLC commenced a claim to recover the amounts owing for CAD $312,303 in April 2022, obtained default judgment in the amount of CAD $314,273 in March 2023. On September 30, 2025, Astor Street LLC took steps to seize assets belonging to the Company. The Company is currently assessing the validity of the claim and default judgment, and whether it is necessary to come to a negotiated resolution. As of March 31, 2026, the amounts payable for promissory notes to Astor Street LLC included in notes payable was $215,223 (CAD $300,000) (December 31, 2025 - $218,882 (CAD $300,000)).\n\n \n\n**NOTE 7 - SEGMENT NOTE**\n\n \n\nThe Company operates as a single operating segment. The Company's CODM is its CEO, who reviews financial information presented on a consolidated basis. The CODM uses revenue, cost of goods sold, consolidated operating margin and net income to assess financial performance and allocate resources. These financial metrics are used by the CODM to make key operating decisions, such as the determination of the rate at which the Company seeks to grow its operating profit margin and the allocation of budget between cost of goods sold, professional fees, and general and administrative expenses.\n\n \n\n \n\n16\n\n*Table of Contents*\n\n \n\n**CANNAPHARMARX, INC.**\n\n**NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**\n\n**FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025**\n\n**(in United States dollars)**\n\n \n\n**NOTE 7 - SEGMENT NOTE (continued)**\n\n \n\n \n\nThe following table presents selected financial information with respect to the Company’s single operating segment for the three months ended March 31, 2026 and 2025:\n\n \n\n \n\n \n\n**2026**\n\n \n\n \n\n2025\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n**Revenue**\n\n \n**$****627,462**\n \n\n \n$335,319\n \n\n**Cost of goods sold**\n\n \n\n \n**1,036,915**\n \n\n \n\n \n837,926\n \n\n**Gross loss**\n\n \n\n \n**(409,453****)**\n \n\n \n(502,607)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n**Operating expenses**\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nGeneral and administrative\n\n \n\n \n**35,814**\n \n\n \n\n \n38,641\n \n\nProfessional fees\n\n \n\n \n**105,856**\n \n\n \n\n \n136,337\n \n\nRoyalty expense\n\n \n\n \n**131,220**\n \n\n \n\n \n-\n \n\nTotal operating expenses\n\n \n\n \n**272,890**\n \n\n \n\n \n174,978\n \n\n**Loss from operations**\n\n \n\n \n**(682,343****)**\n \n\n \n(677,585)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nOther segment items\n\n \n\n \n**364,112**\n \n\n \n\n \n(13,009)\n\nNet loss\n\n \n**$****(318,231****)**\n \n$(690,594)\n\n \n\n**NOTE 8 - SIGNIFICANT EVENTS DURING THE PERIOD**\n\n \n\nOn February 3, 2026, the Company entered into an agreement to settle $50,000 and $10,377 in outstanding note payable principal and accrued interest, respectively, through the issuance of 30,188,500 common shares. As at March 31, 2026, the shares have not been issued.\n\n \n\n \n\n17\n\n*Table of Contents*"}